Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458929 | 0.95 | ALDH1A1 (0.39) | KMT2AMEN1ALDH1A1PTGDR2HPGD | |
| SCHEMBL5458049 | 0.93 | TSHR (0.38) | KMT2AALDH1A1SMN1; SMN2PTGDR2HPGD | |
| SCHEMBL5451031 | 0.89 | ALDH1A1 (0.42) | KMT2AMEN1ALDH1A1PTGDR2HPGD | |
| SCHEMBL5452215 | 0.88 | LMNA (0.39) | KMT2AALDH1A1PTGDR2HPGDNPC1 | |
| SCHEMBL5454884 | 0.86 | ALDH1A1 (0.45) | KMT2AMEN1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5456768 | 0.81 | KMT2A (0.45) | KMT2AMEN1ALDH1A1SMN1; SMN2PTGDR2 | |
| SCHEMBL5452471 | 0.80 | MAPT (0.40) | KMT2AALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL5445292 | 0.79 | TSHR (0.45) | KMT2AMEN1ALDH1A1SMN1; SMN2PTGDR2 | |
| SCHEMBL5458935 | 0.78 | GAA (0.43) | KMT2AALDH1A1SMN1; SMN2PTGDR2GAA | |
| SCHEMBL5444094 | 0.76 | GFER (0.53) | KMT2AMEN1ALDH1A1SMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | KMT2A 1271/4885MEN1 385/4885ALDH1A1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.